" class="no-js "lang="en-US"> Hal Barron - Medtech Alert
Saturday, September 23, 2023
Hal Barron

Hal Barron

About Hal Barron

Hal joined GSK as Chief Scientific Officer and President, R&D on 1 January 2018. He was also appointed to the GSK Board of Directors as an Executive Director.

Hal is responsible for all research and development of our pipeline molecules as well as life-cycle management of the approved medicines. He is a member of the Corporate Executive Team.

Skills and experience

Prior to joining GSK, Hal was President, R&D at Calico LLC (California Life Company), an Alphabet-funded company that uses advanced technologies to increase understanding of lifespan biology. Prior to this, Hal was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President of Development and Chief Medical Officer. Hal was a Non-Executive Director and Chair of the Science & Technology Committee at Juno Therapeutics, Inc until March 2018, when it was acquired by Celgene Corporation.

He holds a Bachelor of Science degree in Physics from Washington University in St Louis and a medical degree from Yale University. He completed his training in Cardiology and Internal Medicine at the University of California, San Francisco.

Hal has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.

External appointments

  • Associate Adjunct Professor, Epidemiology & Biostatistics, University of California, San Francisco
  • Non-Executive Board Director, GRAIL, Inc, an early cancer detection healthcare company
  • Advisory Board Member, Verily Life Sciences LLC, a subsidiary of Alphabet, Inc

Related Story

GSK to Acquire Clinical-stage Biopharmaceutical Company Affinivax, Inc.

June 1 2022

GSK plc (LSE/NYSE: GSK) today announced that it has entered into a definitive agreement to […]

GSK Announces Positive Phase III Efficacy and Safety Data for Daprodustat in Patients with Anaemia Due to Chronic Kidney Disease

November 8 2021

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive results from the Phase III ASCEND (Anaemia Studies in […]

EU Commission Approves Benlysta for Lupus Nephritis

May 5 2021

GlaxoSmithKline plc (GSK) today announced the European Commission has approved the expanded use of intravenous […]

FDA Grants Accelerated Approval for GSK’s JEMPERLI (dostarlimab-gxly) for Women with Recurrent or Advanced dMMR Endometrial Cancer

April 23 2021

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has […]

Lilly, Vir, GSK Announce Positive Topline Data from Phase 2 BLAZE-4 Trial

March 30 2021

Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced […]